ag 1879 has been researched along with sirolimus in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alessi, DR; Arthur, JS; Bain, J; Cohen, P; Elliott, M; Hastie, CJ; Klevernic, I; McLauchlan, H; Plater, L; Shpiro, N | 1 |
| Clemente, CF; Franchini, KG; Lopes-Cendes, I; Marin, TM; Pascoal, VD; Picardi, PK; Saad, MJ; Santos, AM | 1 |
| Kim, DK; Lee, HW; Lee, SC | 1 |
| Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S | 1 |
4 other study(ies) available for ag 1879 and sirolimus
| Article | Year |
|---|---|
The selectivity of protein kinase inhibitors: a further update.
Topics: Amino Acid Sequence; Animals; Cell Line; Drug Design; Enzyme Activation; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Recombinant Proteins; Spodoptera | 2007 |
Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Size; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Kinase 1; Mechanotransduction, Cellular; Myocytes, Cardiac; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Rats, Wistar; Recombinant Fusion Proteins; Ribosomal Protein S6 Kinases; RNA Interference; RNA, Small Interfering; Sirolimus; src-Family Kinases; TOR Serine-Threonine Kinases; Transfection; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2008 |
CD137 ligand-mediated reverse signals increase cell viability and cytokine expression in murine myeloid cells: involvement of mTOR/p70S6 kinase and Akt.
Topics: 4-1BB Ligand; Animals; Carrier Proteins; Cell Adhesion; Cell Line; Cell Survival; Chromones; Cytokines; Enzyme Inhibitors; Immunity, Innate; Immunosuppressive Agents; Intercellular Adhesion Molecule-1; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Macrophage Colony-Stimulating Factor; Macrophages; Male; Mice; Mice, Inbred BALB C; Morpholines; Myeloid Cells; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-akt; Pyrimidines; Recombinant Proteins; Signal Transduction; Sirolimus; src-Family Kinases; TOR Serine-Threonine Kinases; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2009 |
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases | 2011 |